

HHS Public Access

Author manuscript *Ophthalmology*. Author manuscript; available in PMC 2020 June 25.

Published in final edited form as: *Ophthalmology*. 2017 March ; 124(3): e24. doi:10.1016/j.ophtha.2016.07.004.

Re: Kostanyan et al.: Glaucoma structural and functional progression in American and Korean cohorts (Ophthalmology 2016;123:783-788)

Joel S. Schuman, MD^{1,2}, Hiroshi Ishikawa, MD^{1,3,4}, Gadi Wollstein, MD^{1,3,4}

¹Department of Ophthalmology, NYU Langone Medical Center, NYU School of Medicine, New York, New York

²Department of Electrical and Computer Engineering, NYU Tandon School of Engineering, Brooklyn, New York

³UPMC Eye Center, Eye and Ear Institute, Ophthalmology and Visual Science Research Center, Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

⁴Department of Bioengineering, Swanson School of Engineering, University of Pittsburgh, Pittsburgh, Pennsylvania

REPLY: We thank Drs. Ye and Liang for their insightful comments regarding our study.¹ In this study, we tested our hypothesis that "the composition of the participating populations in longitudinal glaucoma studies has a significant effect on the rate of structural and functional progression." We attempted to highlight the potential problem of comparing glaucoma progression rate from studies performed on discrete populations. To this end, we used 2 distinctive cohorts with similar baseline characteristics and used conventional progression analysis methods. We demonstrated that ethnicity, baseline disease severity, disease subtype, and clinical diagnosis can significantly impact the rate of progression and therefore should be considered when comparing glaucoma progression studies. Our goal was not to create the standard of reference for rate of progression in certain ethnicities, disease severities, and so on, but rather to emphasize the need to account for the complex relationship between fundamental population characteristics when comparing progression rate results reported in the literature. Further studies are warranted to determine the naturalized rate of progression in different clinical settings.

Acknowledgments

Financial Disclosures: The authors made the following disclosures:

J.S.S.: Royalties - ZEISS

Supported by grants from the National Institutes of Health, the Eye and Ear Foundation, and Research to Prevent Blindness.

Correspondence: Joel S. Schuman, MD, New York University, Ophthalmology, New York, NY. joel.schuman@nyu.edu.

References

1. Kostanyan T, Sung KR, Schuman JS, et al. Glaucoma structural and functional progression in American and Korean cohorts. Ophthalmology. 2016;123:783–788. [PubMed: 26778345]